With the shelf now effective, selling shareholders can begin distributing shares immediately. Monitor for a prospectus supplement or Form 424B filing indicating the start of sales — that would mark the beginning of actual dilution. The August 2026 private placement already signaled capital needs; this effectiveness removes the final barrier to secondary selling.
Price Chart
Executive Summary
The SEC declared effective Quoin Pharmaceuticals' S-3 registration statement (File No. 333-299021) on September 25, 2026, covering the resale of up to 9,371,895 ADSs by selling shareholders. The company receives no proceeds from this resale shelf, but the effectiveness removes the final regulatory barrier for the selling shareholders to sell shares into the market, creating a persistent overhang of potential dilution.
Key Facts
- Effectiveness date: September 25, 2026
- Registration covers resale of up to 9,371,895 ADSs (representing 328,016,325 ordinary shares)
- Company receives no proceeds from this offering
- Shelf was filed on September 18, 2026, and declared effective 7 days later
- The registered shares include 2,445,800 ADSs issued in an August 2026 private placement, 3,802,130 ADSs issuable upon pre-funded warrants, and 3,123,965 ADSs issuable upon ordinary warrants
Financial Impact
Up to 9,371,895 ADSs (328M ordinary shares) can now be resold; company receives no proceeds. Potential exercise of ordinary warrants could bring up to ~$19.1 million in proceeds to the company, but the primary effect is dilution overhang.
Risk Factors
- Immediate overhang of up to 9.4M ADSs eligible for resale, likely to pressure the stock
- Ordinary warrants, if exercised, would add further dilution and bring modest cash to the company
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003071 |
| Document: 9999999995-26-003071-index.html | 9999999995-26-003071 |
| Document: 9999999995-26-003071.txt | 9999999995-26-003071 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $4.04 | awaiting T+20 | awaiting T+20 | $4.05 (+0.25%) |
Oct 19, 2026 8d ago | ANALYST-UPGRADE | $3.98 | awaiting T+20 | awaiting T+20 | $4.05 (+1.76%) |
Oct 14, 2026 13d ago | 8-K | $4.10 | awaiting T+20 | awaiting T+20 | $4.05 (−1.22%) |
Oct 12, 2026 15d ago | ANALYST-UPGRADE | $4.36 | awaiting T+20 | awaiting T+20 | $4.05 (−7.11%) |
Oct 7, 2026 20d ago | SC 13G/A | $4.55 | awaiting T+20 | awaiting T+20 | $4.05 (+10.99%) |
Oct 2, 2026 25d ago | DEF 14A | $4.56 | awaiting T+20 | awaiting T+20 | $4.05 (−11.09%) |
Sep 28, 2026 4w ago | EFFECT | $5.26 $4.01 | ▲ +23.76% | ▲ +23.73% | $4.05 (+23.00%) |
Sep 22, 2026 5w ago | Press Release | $7.01 $4.04 | ▼ −42.37% | ▼ −41.81% | $4.05 (−42.23%) |
Sep 18, 2026 5w ago | S-3 | $6.90 $3.98 | ▲ +42.32% | ▲ +41.41% | $4.05 (+41.30%) |
Sep 1, 2026 8w ago | Insider Cluster | $6.74 $4.56 | ▼ −32.34% | ▼ −32.01% | $4.05 (−39.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers